Safety and outcome of treatment of latent tuberculosis infection in liver transplant recipients
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Yun Woo | - |
dc.contributor.author | Chung, Hyemin | - |
dc.contributor.author | Kim, Sung-Han | - |
dc.contributor.author | Sung, Heungsup | - |
dc.contributor.author | Ha, Su-Min | - |
dc.contributor.author | Jwa, Eun-Kyoung | - |
dc.contributor.author | Jung, Dong-Hwan | - |
dc.contributor.author | Moon, Deok-Bog | - |
dc.contributor.author | Lee, Sung-Gyu | - |
dc.contributor.author | Lee, Sang-Oh | - |
dc.date.accessioned | 2024-04-29T08:31:47Z | - |
dc.date.available | 2024-04-29T08:31:47Z | - |
dc.date.issued | 2024-06 | - |
dc.identifier.issn | 0300-8126 | - |
dc.identifier.issn | 1439-0973 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/73530 | - |
dc.description.abstract | Purpose Liver transplant (LT) recipients have an increased risk of tuberculosis (TB), which is associated with higher mortality rates. This retrospective cohort study assessed the outcome and tolerability of screening and treatment of latent tuberculosis infection (LTBI) in LT recipients. Methods Between March 2020 and February 2022, all adult LT candidates at our institution were screened for LTBI. The candidates who tested positive for interferon-gamma-releasing assay or met epidemiological or clinical-radiological criteria for LTBI were treated and monitored. Results Among the 857 LT recipients, 199 (23.2%) were diagnosed with LTBI, of which 171 (85.9%) initiated LTBI treatment. The median duration of follow-up was 677 days. Adequate LTBI treatment occurred in 141/171 (82.5%) patients and was discontinued prematurely in 30/171 (17.5%) patients. The most common reason for discontinuation was liver enzyme elevation (11/30, 36.7%), although only five discontinued treatment due to suspicion of isoniazid-associated hepatotoxicity. None of the LTBI-treated patients developed active TB during the follow-up period, while 3.6% (1/28) of untreated LTBI patients and 0.6% (4/658) of patients without LTBI developed TB. Conclusion These findings demonstrate that LTBI screening and treatment is a safe and effective strategy to prevent TB in LT recipients. However, monitoring for adverse events and liver enzyme elevation is recommended. | - |
dc.format.extent | 7 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | SPRINGER HEIDELBERG | - |
dc.title | Safety and outcome of treatment of latent tuberculosis infection in liver transplant recipients | - |
dc.type | Article | - |
dc.identifier.doi | 10.1007/s15010-023-02161-1 | - |
dc.identifier.bibliographicCitation | INFECTION, v.52, no.3, pp 1055 - 1061 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.wosid | 001160320400001 | - |
dc.identifier.scopusid | 2-s2.0-85184938361 | - |
dc.citation.endPage | 1061 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 1055 | - |
dc.citation.title | INFECTION | - |
dc.citation.volume | 52 | - |
dc.type.docType | Article | - |
dc.publisher.location | 독일 | - |
dc.subject.keywordAuthor | Tuberculosis | - |
dc.subject.keywordAuthor | Latent tuberculosis infection | - |
dc.subject.keywordAuthor | Liver transplantation | - |
dc.subject.keywordAuthor | Interferon-gamma-releasing assay | - |
dc.subject.keywordAuthor | Isoniazid | - |
dc.subject.keywordPlus | MANAGEMENT | - |
dc.subject.keywordPlus | PROPHYLAXIS | - |
dc.subject.keywordPlus | DIAGNOSIS | - |
dc.subject.keywordPlus | ASSAY | - |
dc.subject.keywordPlus | RISK | - |
dc.relation.journalResearchArea | Infectious Diseases | - |
dc.relation.journalWebOfScienceCategory | Infectious Diseases | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.